Clik here to view.
Hospira Appeals $80 Million Judgment in Epoetin Alfa Biosimilar Case
As we reported, last month in the Amgen v. Hospira litigation concerning Hospira’s Retacrit (epoetin alfa) biosimilar, the Delaware district court entered final judgment against Hospira, awarding Amgen...
View ArticleClik here to view.
Federal Circuit Round Up: Epoetin Alfa, Adalimumab, Rituximab
April has seen a flurry of biosimilar-related appellate activity before the Federal Circuit. Below are some highlights. The parties in the Amgen v. Hospira BPCIA litigation concerning Hospira’s...
View ArticleClik here to view.
Hospira Asks Federal Circuit to Take Fresh Look at Safe Harbor Ruling in...
Last month, a three-judge panel of the Federal Circuit affirmed a Delaware district court’s judgment of infringement against Hospira and $70 million damages award to Amgen in the parties’ BPCIA...
View ArticleClik here to view.
White Paper Investigates Biosimilar Competition and Price Reduction
In March 2021, researchers from Harvard Medical School, Harvard University, and Brigham and Women’s Hospital published a white paper exploring the link between entry of biosimilars under The Biological...
View Article